HOUSTON and DENVER, May 02, 2022 (GLOBE NEWSWIRE) -- Houston Methodist and Colorado-based BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced a new collaboration to advance cutting-edge remote monitoring and analytics technologies across the healthcare continuum, from in-hospital to at-home. The recently executed Memorandum of Understanding (MOU) identifies several areas of strategic focus for improving patient care, increasing clinical workflow efficiencies, and reducing the burden on healthcare systems.
BioIntelliSense’s FDA-cleared BioSticker™ and medical grade BioButton® wearable devices, along with its algorithmic-based data services, enable effortless remote data capture and continuous multi-parameter monitoring of 20+ biometrics for up to 30 days on a single device. These patient-friendly wearables capture and wirelessly transmit up to 1,440 sets of vital sign measurements per day at a fraction of the cost of traditional, manually-collected vital sign measurements 4-6 times per day. In combination with BioIntelliSense’s advanced BioCloud™ data analytics, patient-specific trending and clinical intelligence allow for early detection of adverse trends and proactive interventions.
“This new strategic collaboration with BioIntelliSense exemplifies Houston Methodist’s continued commitment to advancing world-class expertise and greater efficiency to deliver the highest quality and most impactful care,” said Dr. Sarah Pletcher, Vice President and Executive Medical Director, Strategic Innovation, Houston Methodist. “This collaboration keeps the patient at the center as we continue to maximize our leadership in healthcare innovation.”
The collaboration will also address the rising costs and burdens of the growing healthcare workforce shortage. BioIntelliSense and Houston Methodist will jointly design and develop a state-of-the-art virtual care control center at Houston Methodist to enable seamless, scalable, continuous monitoring of patients across in-hospital to home care settings.
“Data-driven remote patient monitoring that is simple, clinically accurate, and cost-effective, is the future of healthcare delivery,” said James Mault, MD, Founder and CEO of BioIntelliSense. “We are proud to work alongside our partners at Houston Methodist to pioneer a continuous care model that provides actionable data and clinical intelligence to enable our overburdened healthcare workforce take better care of patients in any care setting.”
The MOU further establishes the use of leading biosensor technology and the development of advanced algorithms, care models, and data analytics for monitoring and treating a range of complex conditions spanning heart and vascular, orthopedics, oncology, infectious diseases, transplants, and others.
Learn more about how BioIntelliSense is making early detection simple™ at ATA22 Annual Conference and Expo, May 1-3, 2022 in Boston, Massachusetts.
Media Contact:
Houston Methodist
Laureen Lucas
llucas@llpublicrelations.com
BioIntelliSense, Inc.
Eric Schudiske
eric@s2spr.com
______________________________________________________________________
ABOUT HOUSTON METHODIST
Houston Methodist is one of the nation’s leading health systems and academic medical centers. The health system consists of eight hospitals: Houston Methodist Hospital, its flagship academic hospital in the Texas Medical Center, six community hospitals and one long-term acute care hospital throughout the Greater Houston metropolitan area. Houston Methodist also includes a research institute; a comprehensive residency program; international patient services; freestanding comprehensive care, emergency care and imaging centers; and outpatient facilities. Houston Methodist employs more than 27,000 people and had more than 1.6 million outpatient visits and more than 132,000 admissions in 2021. For more information on Houston Methodist, see houstonmethodist.org
ABOUT BIOINTELLISENSE
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The FDA-cleared BioSticker™ and medical-grade BioButton® devices make remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade remote care from in-hospital to home.
Learn how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services or visit our website at BioIntelliSense.com. Follow BioIntelliSense on Twitter and LinkedIn for the latest news and information.
